helping to put people with type 1 diabetes and their siblings in touch with researchers running trials and studies
Welcome to ADDRESS-2
the research project that is learning about the characteristics of people newly diagnosed with type 1 with diabetes in the UK, and at the same time supporting other research into type 1 diabetes.
We are looking for siblings to help too.
We collect information and optional blood samples to help us understand more about type 1 diabetes.
We aim to give people who join ADDRESS-2 information about other type 1 diabetes research for which they might be eligible, and put them in touch with the teams running the research.
Have you been diagnosed with type 1 diabetes in the last 6 months?
Are you interested in helping with research?
Find out about the clinical trials and research studies looking for participants, that ADDRESS-2 is supporting.
We are the recruitment support network partner in the Type 1 Diabetes UK Immunotherapy Consortium.
ADDRESS-2 can help to identify and contact candidates for your study.
ADDRESS-2 has been helping to put people with type 1 diabetes in contact with researchers running trials and other studies.
If you are not eligible to join ADDRESS-2 there a number of ways to get information about type 1 diabetes research that might be of interest to you.
ADDRESS-2 has been helping researchers to recruit to their trials and other studies.
ADDRESS-2 is now supporting a study to understand better how much insulin people with type 1 diabetes can make within the first year of diagnosis.Read more
Diabetes UK, co-funder of ADDRESS-2
ADDRESS-2 is helping the UK to develop as a world leading place to do the types of immunotherapy studies that are needed to move forward treatment for type 1 diabetes.
JDRF, co-funder of ADDRESS-2
The Juvenile Diabetes Research Foundation is honored to be involved in this important initiative to encourage people with type 1 diabetes to get involved with research.
Watch Diabetes UK's new video about type 1 diabetes.
Read the BBC report about a therapy to retrain the immune system in type 1 diabetes; results from a trial supported by ADDRESS-2.
Read the first paper reporting results from ADDRESS-2 published in BMJ Open.
Read about ADDRESS-2 on the National Institute for Health Research website.